Amgen’s Cancer Drug Shows Real Promise

Big news in cancer research: Amgen’s new drug, Bemarituzumab, just proved it can help late-stage gastric cancer patients live longer when combined with chemo. The trial hit its main goal, and the results are especially hopeful for people whose tumors overexpress the FGFR2b protein. There are some side effects (think eye issues and nausea), but this could be a real game-changer for nearly 1 million new patients each year. Stocktwits is buzzing, but AMGN stock is still a bit of a rollercoaster! #CancerResearch #Amgen #MedicalBreakthrough #Health #BodyHealth